Cancer Vaccine for Ovarian Cancer

Palo Alto (17 mi)

Matthew S. Block, M.D., Ph.D. - Doctors ...

Overseen byMatthew S. Block, MD, PhD

Age: 18+

Sex: Female

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Mayo Clinic

No Placebo Group

Trial Summary

What is the purpose of this trial?This pilot clinical trial studies the safety and immunogenicity of vaccine therapy in treating patients with stage IIIC-IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer following surgery and chemotherapy. Vaccines made from a person's peptide treated white blood cells may help the body build an effective immune response to kill tumor cells.

Eligibility Criteria

This trial is for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who've had surgery and one round of chemo. They should have no signs of disease currently, be in good physical condition, able to consent, return for follow-ups at Mayo Clinic Rochester, provide blood samples, get a tetanus shot and live more than 6 months.

Inclusion Criteria

My cancer diagnosis is advanced ovarian, fallopian tube, or peritoneal cancer.

I currently show no signs of my cancer returning, based on exams and tests.

I am fully active or restricted in physically strenuous activity but can do light work.

Exclusion Criteria

I had a heart attack less than 6 months ago or have heart failure needing constant treatment.

My ovarian cancer is of a type that grows slowly.

I am immunocompromised or HIV positive and on antiretroviral therapy.

I am not on any experimental drugs for my cancer.

I have been diagnosed with an autoimmune disease.

I do not have any uncontrolled illnesses that would affect my participation.

I have not taken more than 5 mg of prednisone or equivalent daily in the last 4 weeks.

Treatment Details

The study tests the safety and immune response to a vaccine therapy made from the patient's own white blood cells treated with peptides. It targets women with stage IIIC-IV ovarian epithelial cancer post-surgery and chemotherapy.

1Treatment groups

Experimental Treatment

Group I: Treatment (vaccine therapy)Experimental Treatment2 Interventions

INDUCTION PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 weeks for 5 courses in the absence of disease progression or unacceptable toxicity. MAINTENANCE PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 months for 7 courses in the absence of disease progression or unacceptable toxicity.